Neonates have high risk for infection of
Klebsiella pneumoniae due to the undeveloped body physiology, resulting in high morbidity and mortality (
1,
2). Approximately one million neonatal deaths are caused by infection, which is frequently associated with contaminated medical devices and instrumentation. Factors, like high occupation rates and extensive use of antibiotics, are inevitably leading to the prevalence of drug-resistant strains. As one of the most frequently isolated bacteria in a hospital setting,
K. pneumoniae is resistant to many antimicrobial agents by producing a variety of drug-resistance genes, including extended spectrum β-lactamases (ESBLs), AmpC β-lactamases, 16S rRNA methylases, aminoglycoside modifying enzymes and carbapenemases (
3).
The increasing number of strains harboring extended-spectrum β-lactamase-producing
Enterobacteriaceae (resistant to penicillins, cephalosporins and monobactams) and AmpC β-lactamases is a major treatment challenge. Given the side-effects of antibiotics in newborns, carbapenems are often the only therapeutic option for treating severe infection caused by mutidrug-resistant
Enterobacteriaceae (
4). In recent years, carbapenem-resistant
Enterobacteriaceae in infants and children has become an emerging nosocomial pathogen worldwide.
Carbapenem-resistance is primarily mediated by the production of carbapenemases, which hydrolyze β-lactam of all classes, including the most potent class, carbapenems (
5). Molecular structural classifications of carbapenemases include Ambler class A, B and D. The metallo-β-lactamases (MBLs) belong to class B carbapenemases that includes Verona integron-encoded MBL (VIM), IMP (IMP-type MBL) or New Delhi MBL (NDM) (
6). Carbapenemases carried on mobile genetic elements, such as transposons or plasmids harboring resistance genes, can transfer into strains capable of efficient human to human transmission (
7). The carbapenemase New Delhi metallo-beta-lactamase-1 (NDM-1) is one of the most recently reported MBLs. It was originally identified in India, but now has a global distribution (
8).
A few studies on spread of carbapenemase-producing
K. pneumonia in newborns have been reported. In August 2011, a nosocomial outbreak of NDM-1-producing
K. pneumonia was reported in Colombia involving six patients who were admitted to the neonatal unit of a general hospital in Bogota (
9). An outbreak of carbapenemase-producing
K. pneumoniae sequence type (ST) 258 was investigated in a neonatal intensive care unit (NICU) in Palermo, Italy and carbapenemase-producing
K. pneumoniae was isolated from 10 out of 54 neonates admitted in the outbreak period (
10). In China, an outbreak caused by imipenemase-4 (IMP-4)-producing
K. pneumonia occurred in a neonatal intensive care unit in 2011 (
11). Another outbreak of colonization by carbapenemase-producing
K. pneumoniae occurred in a neonatal intensive care unit of Peking union Medical college hospital, China in 2015 (
2).